Blar i forfatter "Nyakas, Marta Sølvi"

Viser treff 1-2 av 2

    • AXL inhibition improves BRAF-targeted treatment in melanoma 

      Nyakas, Marta Sølvi; Fleten, Karianne Giller; Haugen, Mads Haugland; Engedal, Nikolai; Sveen, Christina; Farstad, Inger Nina; Flørenes, Vivi Ann; Prasmickaite, Lina; Mælandsmo, Gunhild Mari; Vasiliauskaite, Kotryna (Journal article; Tidsskriftartikkel; Peer reviewed, 2022)
      More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to a more aggressive mesenchymal phenotype, attributed with AXL<sup>high</sup> molecular profle in melanoma, has been recently linked to such event, limiting treatment efcacy. In the current study, ...

    • Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma 

      Nyakas, Marta Sølvi; Aamdal, Elin; Jacobsen, Kari Dolven; Guren, Tormod Kyrre; Aamdal, Steinar; Hagene, Kirsten Thorin; Brunsvig, Paal Fr.; Yndestad, Arne; Halvorsen, Bente; Tasken, Kristin Austlid; Aukrust, Pål; Mælandsmo, Gunhild Mari; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-03-01)
      New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients with metastatic or unresectable malignant melanoma, receiving treatment with ipilimumab in a national ...